Results 61 to 70 of about 756 (101)

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Journal of Asthma and Allergy, 2019
Jean-Pierre Llanos,1 Christopher F Bell,1 Elizabeth Packnett,2 Ellen Thiel,2 Debra E Irwin,2 Beth Hahn,1 Hector Ortega3 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Truven Health Analytics, An IBM Watson Health Company, Ann ...
Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H   +6 more
doaj  

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3819-3830, November 2026.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Evaluating the Impact of Outcome Delay on the Efficiency of Sample Size Re‐Estimation

Pharmaceutical Statistics, Volume 25, Issue 6, November/December 2026.
ABSTRACT Sample size re‐estimation (SSR) can be a powerful tool to ensure that a clinical trial meets its pre‐specified power requirements when uncertainty regarding a design parameter exists at the planning stage. However, long‐term primary endpoints can be harmful to the efficiency of this trial design.
Aritra Mukherjee, Michael J. Grayling, James M. S. Wason   +2 more
wiley   +1 more source

Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Background Biologic therapies can control severe asthma and may modify its natural history beyond symptom control. However, step‐down is not standardized, and its safety has not been clearly established. Methods This single‐center retrospective cohort study reviewed adults with severe asthma on biologics (January 2019–May 2024).
Nagihan Orhan Özer, Betül Özdel Öztürk, Begüm Görgülü Akın, Ceren Kaplankıran, Şadan Soyyiğit   +4 more
wiley   +1 more source

Eosinophilia Reflects Type 2 Immune Activation in Newly Diagnosed Bullous Pemphigoid, With No Evidence of Charcot‐Leyden Crystals

Allergy, EarlyView.
Janik Fleißner, Tassilo Dege, Sandrine Benoit, Matthias Goebeler, Andreas Kerstan   +4 more
wiley   +1 more source

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

Journal of Asthma and Allergy, 2020
Jean-Pierre Llanos,1 Hector Ortega,1 Michael Bogart,2 Elizabeth R Packnett,3 Janna Manjelievskaia,3 Christopher F Bell,2 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2US Value Evidence and Outcomes, US Medical ...
Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B   +6 more
doaj  

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Background Aspirin‐exacerbated respiratory disease (AERD), also termed nonsteroidal anti‐inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase‐1 inhibitors, frequently resulting in severe, treatment‐refractory airway disease ...
Jennifer K. Priessnitz, Anastasia Hagopian, Alison J. Patev, Joseph K. Han, Kent K. Lam   +4 more
wiley   +1 more source

Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Scientific Reports
To date, most studies to identify biomarkers associated with response to the anti-interleukin 5 agent, mepolizumab, and to the anti-immunoglobulin E agent, omalizumab have focused on clinically available biomarkers, such as the peripheral blood ...
Ayobami Akenroye, Tanawin Nopsopon, Jonathan J. Hacker, Tanya M. Laidlaw   +3 more
doaj   +1 more source

The National Health and Medical Research Council Research Impact Indicators: Unveiling Omissions and Blind Spots, and Positioning for Change

Health Promotion Journal of Australia, Volume 37, Issue 4, October 2026.
ABSTRACT Issue Addressed This study assesses how the concept of (health) research impact has been operationalised in National Health and Medical Research Council (NHMRC) Impact Case Studies, and if and how lived experience research priorities have been considered, to ascertain implications for Australian health and medical research.
Nizam Abdu, Maria Unwin, Caroline Robertson, Oliver Black (Anaiwan), Victoria J. Palmer, Amanda J. Wheeler, Amanda L. Neil   +6 more
wiley   +1 more source

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

ClinicoEconomics and Outcomes Research, 2022
Bassam Mahboub,1 Ahmed Mohy,2 Islam El-Amir,2 Tamara Lukić,3 Raef Gouhar,4 Saeed Noibi5 1Pulmonary Medicine Department, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates; 2Medical Affairs Department, GSK, Jeddah, Kingdom of ...
Mahboub B, Mohy A, El-Amir I, Lukić T, Gouhar R, Noibi S   +5 more
doaj